278 related articles for article (PubMed ID: 27655682)
21. Label-free microfluidic enrichment of cancer cells from non-cancer cells in ascites.
Stone NE; Raj A; Young KM; DeLuca AP; Chrit FE; Tucker BA; Alexeev A; McDonald J; Benigno BB; Sulchek T
Sci Rep; 2021 Sep; 11(1):18032. PubMed ID: 34504124
[TBL] [Abstract][Full Text] [Related]
22. A Pan-ALDH1A Inhibitor Induces Necroptosis in Ovarian Cancer Stem-like Cells.
Chefetz I; Grimley E; Yang K; Hong L; Vinogradova EV; Suciu R; Kovalenko I; Karnak D; Morgan CA; Chtcherbinine M; Buchman C; Huddle B; Barraza S; Morgan M; Bernstein KA; Yoon E; Lombard DB; Bild A; Mehta G; Romero I; Chiang CY; Landen C; Cravatt B; Hurley TD; Larsen SD; Buckanovich RJ
Cell Rep; 2019 Mar; 26(11):3061-3075.e6. PubMed ID: 30865894
[TBL] [Abstract][Full Text] [Related]
23. Correlation analysis of cancer stem cell marker CD133 and human endogenous retrovirus (HERV)-K env in SKOV3 ovarian cancer cells.
Kim DY; Kim H; Ko EJ; Koh SB; Kim H; Lee JY; Lee CM; Eo WK; Kim KH; Cha HJ
Genes Genomics; 2024 Apr; 46(4):511-518. PubMed ID: 38457096
[TBL] [Abstract][Full Text] [Related]
24. DC-CIK cells derived from ovarian cancer patient menstrual blood activate the TNFR1-ASK1-AIP1 pathway to kill autologous ovarian cancer stem cells.
Qin W; Xiong Y; Chen J; Huang Y; Liu T
J Cell Mol Med; 2018 Jul; 22(7):3364-3376. PubMed ID: 29566310
[TBL] [Abstract][Full Text] [Related]
25. Clonogenically Culturing and Expanding CD34+ Liver Cancer Stem Cells in Vitro.
Park SC; Zeng C; Tschudy-Seney B; Nguyen NT; Eun JR; Zhang Y; Ramsamooj R; Zhang Y; Zhao M; Theise ND; Zhou H; Zern MA; Duan Y
Stem Cells Dev; 2015 Jul; 24(13):1506-14. PubMed ID: 25867583
[TBL] [Abstract][Full Text] [Related]
26. A Validation Study of CD133 as a Reliable Marker for Identification of Colorectal Cancer Stem-Like Cells.
You CZ; Xu H; Zhao FS; Dou J
Bull Exp Biol Med; 2024 Jan; 176(3):369-375. PubMed ID: 38340198
[TBL] [Abstract][Full Text] [Related]
27. METTL3 promotes oxaliplatin resistance of gastric cancer CD133+ stem cells by promoting PARP1 mRNA stability.
Li H; Wang C; Lan L; Yan L; Li W; Evans I; Ruiz EJ; Su Q; Zhao G; Wu W; Zhang H; Zhou Z; Hu Z; Chen W; Oliveira JM; Behrens A; Reis RL; Zhang C
Cell Mol Life Sci; 2022 Feb; 79(3):135. PubMed ID: 35179655
[TBL] [Abstract][Full Text] [Related]
28. Mesenchymal stem cell-like properties of CD133+ glioblastoma initiating cells.
Pavon LF; Sibov TT; de Oliveira DM; Marti LC; Cabral FR; de Souza JG; Boufleur P; Malheiros SM; de Paiva Neto MA; da Cruz EF; Chudzinski-Tavassi AM; Cavalheiro S
Oncotarget; 2016 Jun; 7(26):40546-40557. PubMed ID: 27244897
[TBL] [Abstract][Full Text] [Related]
29. Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer.
Shah NR; Tancioni I; Ward KK; Lawson C; Chen XL; Jean C; Sulzmaier FJ; Uryu S; Miller NL; Connolly DC; Schlaepfer DD
Gynecol Oncol; 2014 Jul; 134(1):104-11. PubMed ID: 24786638
[TBL] [Abstract][Full Text] [Related]
30. Phenotyping clonal populations of glioma stem cell reveals a high degree of plasticity in response to changes of microenvironment.
Innes JA; Lowe AS; Fonseca R; Aley N; El-Hassan T; Constantinou M; Lau J; Eddaoudi A; Marino S; Brandner S
Lab Invest; 2022 Feb; 102(2):172-184. PubMed ID: 34782726
[TBL] [Abstract][Full Text] [Related]
31. CD133, CD47, and PD-L1 Expression in Ovarian High-grade Serous Carcinoma and Its Association with Metastatic Disease: A Cross-sectional Study.
Masadah R; Ikram D; Riadi R; Tangdiung Y; Nelwan BJ; Ghaznawie M; Rauf S; Faruk M
Asian Pac J Cancer Prev; 2024 Jan; 25(1):249-255. PubMed ID: 38285791
[TBL] [Abstract][Full Text] [Related]
32. Cancer stem cells in lung cancer: Evidence and controversies.
Alamgeer M; Peacock CD; Matsui W; Ganju V; Watkins DN
Respirology; 2013 Jul; 18(5):757-64. PubMed ID: 23586700
[TBL] [Abstract][Full Text] [Related]
33. Protein CD133 as a tumor stem cell marker.
Grabovenko FI; Kisil OV; Pavlova GV; Zvereva ME
Zh Vopr Neirokhir Im N N Burdenko; 2022; 86(6):113-120. PubMed ID: 36534632
[TBL] [Abstract][Full Text] [Related]
34. Ovarian Cancer Stem Cells: Unraveling a Germline Connection.
Parte SC; Smolenkov A; Batra SK; Ratajczak MZ; Kakar SS
Stem Cells Dev; 2017 Dec; 26(24):1781-1803. PubMed ID: 29078734
[TBL] [Abstract][Full Text] [Related]
35. Can CD133 Be Regarded as a Prognostic Biomarker in Oncology: Pros and Cons.
Gisina A; Kim Y; Yarygin K; Lupatov A
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139228
[TBL] [Abstract][Full Text] [Related]
36. PTTG1: a Unique Regulator of Stem/Cancer Stem Cells in the Ovary and Ovarian Cancer.
Parte S; Virant-Klun I; Patankar M; Batra SK; Straughn A; Kakar SS
Stem Cell Rev Rep; 2019 Dec; 15(6):866-879. PubMed ID: 31482269
[TBL] [Abstract][Full Text] [Related]
37. CD49f(high) cells retain sphere-forming and tumor-initiating activities in human gastric tumors.
Fukamachi H; Seol HS; Shimada S; Funasaka C; Baba K; Kim JH; Park YS; Kim MJ; Kato K; Inokuchi M; Kawachi H; Yook JH; Eishi Y; Kojima K; Kim WH; Jang SJ; Yuasa Y
PLoS One; 2013; 8(8):e72438. PubMed ID: 24015244
[TBL] [Abstract][Full Text] [Related]
38. Simultaneously target of normal and stem cells-like gastric cancer cells via cisplatin and anti-CD133 CAR-T combination therapy.
Han Y; Sun B; Cai H; Xuan Y
Cancer Immunol Immunother; 2021 Oct; 70(10):2795-2803. PubMed ID: 33635343
[TBL] [Abstract][Full Text] [Related]
39. Bioengineered adipose-derived stem cells for targeted enzyme-prodrug therapy of ovarian cancer intraperitoneal metastasis.
Malekshah OM; Sarkar S; Nomani A; Patel N; Javidian P; Goedken M; Polunas M; Louro P; Hatefi A
J Control Release; 2019 Oct; 311-312():273-287. PubMed ID: 31499084
[TBL] [Abstract][Full Text] [Related]
40. Expressions of Putative Cancer Stem Cell Markers, CD44 and CD133, are Correlated with Pathological Tumour Stage in Gastric Adenocarcinoma.
Duzcu SE; Astarci HM; Tunc N; Boran C
J Coll Physicians Surg Pak; 2021 May; 31(5):553-558. PubMed ID: 34027868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
